New York State Common Retirement Fund Decreases Stake in Pulse Biosciences, Inc. (NASDAQ:PLSE)

The New York State Common Retirement Fund is a public pension fund that manages the retirement savings of state employees and retirees in New York. The fund has been investing in Pulse Biosciences, Inc. NASDAQPLSE since at least 2018, according to its filings with the Securities and Exchange Commission (SEC).

In the third quarter of 2021, the fund sold 6,829 shares of Pulse Biosciences stock, reducing its stake in the company by 45.2%. After the sale, the fund owned 8,271 shares of the company's stock, which represents a 34.8% ownership stake in the company.

Pulse Biosciences is a biotechnology company that develops and commercializes products for the treatment of cancer and other diseases. The company's flagship product is its proprietary immunotherapy platform, which uses genetically engineered T cells to target and destroy cancer cells.

The reasons behind the fund's decision to sell its stake in Pulse Biosciences are not disclosed in the SEC filing. However, it is worth noting that the company has been facing several challenges in recent years, including regulatory hurdles and competition from other immunotherapy companies. In addition, the company's stock price has been volatile, with significant fluctuations in value over the past year.

Overall, while the New York State Common Retirement Fund's decision to sell its stake in Pulse Biosciences may be seen as a vote of confidence in the company's future prospects, it is also a reminder that investing in individual stocks carries inherent risks and uncertainties.